List of Excipients in Branded Drug BUPIVACAINE HYDROCHLORIDE WITH DEXTROSE

Generic Drugs Containing BUPIVACAINE HYDROCHLORIDE WITH DEXTROSE

Company	Ingredient	NDC	Excipient
B Braun Medical Inc	bupivacaine hydrochloride with dextrose	0264-9379	ANHYDROUS DEXTROSE
B Braun Medical Inc	bupivacaine hydrochloride with dextrose	0264-9379	HYDROCHLORIC ACID
B Braun Medical Inc	bupivacaine hydrochloride with dextrose	0264-9379	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in BUPIVACAINE HYDROCHLORIDE WITH DEXTROSE?

# Of NDCs	Excipient
1	ANHYDROUS DEXTROSE
1	HYDROCHLORIC ACID
1	SODIUM HYDROXIDE

Bupivacaine Hydrochloride With Dextrose: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

Bupivacaine hydrochloride with dextrose is a mature, preservative-free spinal anesthetic product. Its commercial value is based on reliable supply, sterile packaging, hospital contracts, and regulatory execution rather than core-molecule exclusivity. The principal formulation is hyperbaric bupivacaine hydrochloride 0.75% in dextrose 8.25%, supplied for intrathecal administration in single-dose containers.

The strongest opportunities are an ANDA-based generic, contract manufacturing, ready-to-use presentations, improved packaging, and supply-chain differentiation. Conventional composition patents and regulatory exclusivity do not present a meaningful barrier to entry.

What is bupivacaine hydrochloride with dextrose?

Bupivacaine hydrochloride with dextrose is a sterile injectable solution used for spinal anesthesia. The formulation combines:

Component	Typical concentration or function
Bupivacaine hydrochloride	7.5 mg/mL, equivalent to 0.75% bupivacaine
Dextrose	82.5 mg/mL, equivalent to 8.25% dextrose
Water for Injection	Vehicle
Preservative	None
Route	Intrathecal, under labeled conditions
Dosage form	Sterile single-dose injection

Dextrose increases solution density, making the formulation hyperbaric relative to cerebrospinal fluid. Clinicians can use patient positioning and solution density to influence the cephalad or caudad spread of spinal anesthesia. The dextrose is therefore a functional excipient, not merely a bulking agent.

The principal reference product is commonly marketed as Marcaine Spinal or bupivacaine hydrochloride in dextrose injection. Current labeling identifies the product as preservative-free and intended for single-dose use. The product is distinct from plain bupivacaine hydrochloride injection, which generally lacks dextrose and is used for infiltration, peripheral nerve block, epidural anesthesia, or other regional techniques depending on concentration and labeling. (Pfizer, 2023; DailyMed, 2024)

What excipients are used in the formulation?

The excipient strategy is intentionally narrow. Dextrose provides the principal formulation function, while Water for Injection provides the vehicle. The absence of preservatives is important because the product is administered intrathecally.

Why dextrose is commercially important

Dextrose provides hyperbaricity and affects the distribution of bupivacaine in cerebrospinal fluid. Its concentration must remain within a tightly controlled range because changes in density can alter clinical behavior, including block spread and duration.

A generic sponsor must therefore control:

• Dextrose concentration and assay.
• Solution density and specific gravity.
• Osmolality.
• pH.
• Bupivacaine concentration and uniformity.
• Particulate matter.
• Sterility and bacterial endotoxins.
• Container closure integrity.
• Extractables and leachables.
• Stability after sterilization and throughout shelf life.

Substitution of dextrose with another carbohydrate or osmotic agent would create a materially different formulation and could require additional clinical and regulatory support. Dextrose is the lower-risk excipient for an ANDA because it matches the reference product’s established functional profile.

Why preservatives are not attractive

Benzyl alcohol, chlorobutanol, parabens, and other antimicrobial preservatives are poor candidates for an intrathecal product. Preservative-free presentation reduces neurotoxicity concerns and aligns with the established product profile. A preservative-based formulation could trigger a more difficult equivalence and safety assessment.

Is sodium chloride needed?

A sponsor should not assume that sodium chloride is interchangeable with dextrose. Sodium chloride can modify tonicity but does not reproduce the same hyperbaric profile. It also changes ionic strength, osmolality, and potentially formulation behavior. A sodium chloride formulation would be better positioned as a differentiated product requiring separate regulatory and clinical analysis rather than as a direct generic substitute.

What patents protect bupivacaine hydrochloride with dextrose?

The conventional bupivacaine hydrochloride and dextrose composition is a legacy formulation. Public FDA product records do not indicate a meaningful current patent barrier covering the basic 0.75% bupivacaine hydrochloride in 8.25% dextrose solution.

Exclusivity category	Commercial assessment
New chemical entity exclusivity	Expired
Core bupivacaine composition patents	Expired or commercially irrelevant
Conventional dextrose solution patents	No apparent blocking estate
Current Orange Book patent risk	Low for the legacy formulation
Biosimilar exclusivity	Not applicable
Generic substitution risk	High

Bupivacaine was approved decades ago, and generic bupivacaine products have been marketed for many years. Any historical patents covering the active ingredient or basic injectable formulation would have expired long before a current launch program.

A sponsor should still review the current FDA Orange Book and relevant product-specific FDA records before filing. The most material freedom-to-operate risks are more likely to arise from manufacturing processes, container systems, packaging, or a novel delivery technology than from the conventional solution itself. (FDA, 2024a; FDA, 2024b)

When does bupivacaine hydrochloride with dextrose lose exclusivity?

The product has already lost its practical market exclusivity. FDA approval of bupivacaine products dates to the early modern era of local anesthetic regulation, and the reference product is now exposed to generic competition.

No current NCE, orphan-drug, pediatric, or other regulatory exclusivity period is expected to block an ANDA for the conventional product. A new sponsor would generally pursue a 505(j) abbreviated new drug application if it can match the reference product’s dosage form, strength, route, active ingredient, and relevant quality attributes.

Generic launch timeline

A conventional development program can follow this sequence:

Stage	Primary activity
Formulation development	Match dextrose concentration, density, pH, osmolality, and bupivacaine assay
Analytical method development	Validate assay, impurities, particulate, sterility, and endotoxin methods
Container selection	Qualify ampule or vial, stopper, seal, and label system
Stability program	Conduct long-term, accelerated, photostability, and in-use studies as applicable
ANDA preparation	Submit CMC, bioequivalence justification, labeling, and facility information
FDA review	Resolve deficiency letters and facility inspection issues
Launch	Commercialize after approval, subject to Paragraph IV and litigation risk

For a solution product, comparative clinical trials are often avoidable when the formulation and route are sufficiently matched. The critical evidence is usually pharmaceutical equivalence and pharmaceutical quality, including comparative physicochemical properties.

What is the Orange Book status of the product?

The Orange Book status depends on the specific reference-listed drug and FDA product record. The conventional bupivacaine hydrochloride with dextrose product is not generally characterized by a live, high-value patent estate comparable to newer branded injectables.

The commercial review should distinguish among:

1. The specific reference-listed drug for the 0.75% hyperbaric formulation.
2. Plain bupivacaine hydrochloride injection products.
3. Liposomal bupivacaine products such as EXPAREL.
4. Different strengths, routes, and dosage forms.
5. New delivery systems and sustained-release formulations.

A sponsor should not rely on the absence of patents for one bupivacaine product when evaluating another. Liposomal bupivacaine, for example, has a separate formulation and delivery technology profile and is not a substitute for conventional hyperbaric bupivacaine in an ANDA analysis.

Are Paragraph IV challenges likely?

A Paragraph IV certification is possible if a relevant patent is listed for the selected reference product. For the conventional legacy formulation, the practical likelihood of a valuable Paragraph IV dispute is low because the core product is old and generic competition is established.

The more likely commercial outcomes are:

• Paragraph III certification where a listed patent exists but has not expired.
• Paragraph IV certification against a marginal or later-issued patent.
• No-patent certification if the reference product has no relevant listed patents.
• Administrative or CMC delay rather than patent litigation.

Any Paragraph IV exposure would probably involve a later patent directed to packaging, a manufacturing process, a specific presentation, or a formulation modification. A sponsor should assess listed patents at filing because FDA patent records can change over time.

What formulation patents could protect a new product?

The basic bupivacaine-dextrose solution is difficult to differentiate through patenting. Commercially stronger patent targets include the following.

H3: Density-controlled spinal formulations

A patent could focus on a defined density range, osmolality range, pH range, or concentration relationship that produces a specified block profile. The claims would need credible technical support and meaningful distinction from the established hyperbaric formulation.

H3: Reduced-volume presentations

A small-volume ampule or prefilled syringe could improve operating-room workflow. Patent value would depend on a technical feature, such as dose accuracy, low dead volume, container compatibility, or a validated stability advantage.

H3: Novel container closure systems

Glass ampules are established and low-cost. Polymer containers, syringes, or specialty cartridges may provide breakage reduction or automation benefits but can create extractables, leachables, adsorption, and permeability risks. A patent directed only to packaging may have limited commercial value unless it solves a documented hospital or manufacturing problem.

H3: Combination or adjunct formulations

Adding clonidine, dexmedetomidine, opioids, bicarbonate, or other agents would create a new formulation and clinical product rather than a simple generic. Compatibility, preservative status, neurotoxicity, stability, and dosing would require separate development.

H3: Sustained-release bupivacaine

Liposomal or depot delivery is a separate competitive category. It can command higher pricing but requires substantial formulation, clinical, and patent investment. It does not directly compete with the low-cost hyperbaric spinal product in every procedure.

What commercial opportunities exist?

1. ANDA generic launch

The clearest opportunity is a conventional generic matching the reference product. Development priorities are low formulation risk, robust sterile processing, and reliable supply. Price competition will be substantial, so cost of goods and manufacturing scale will determine viability.

2. Contract manufacturing

Hospitals and anesthesia distributors value dependable supply of commonly used injectables. A manufacturer with sterile fill-finish capacity can use bupivacaine hydrochloride with dextrose as part of a broader regional anesthesia portfolio.

3. Ready-to-use packaging

Potential formats include:

• Single-dose glass ampules.
• Unit-dose vials.
• Terminally sterilized polymer containers.
• Ready-to-administer syringes, subject to regulatory and stability requirements.

The best opportunity is operational rather than pharmacological: reduced preparation time, fewer medication errors, clearer labeling, and easier inventory management.

4. Institutional supply contracts

The product is used in hospitals, ambulatory surgery centers, obstetric anesthesia, orthopedic surgery, and other procedural settings. Buyers typically assess landed price, back-order history, quality performance, package configuration, and distributor availability.

5. Geographic expansion

The active ingredient and excipient platform are globally familiar, but regulatory requirements differ. The primary regional variables are:

• Pharmacopoeial standards.
• Sterile manufacturing expectations.
• Local reference products.
• Container and labeling requirements.
• Import controls.
• Hospital procurement structures.
• Local rules for intrathecal products.

A sponsor can often leverage common CMC data across jurisdictions, but the reference product and bioequivalence pathway may differ by country.

How strong is the patent estate?

The patent estate for the conventional product is weak from an exclusivity perspective and moderate from a freedom-to-operate perspective.

Factor	Assessment
Active ingredient patent barrier	Low
Basic composition patent barrier	Low
Regulatory exclusivity	None expected
Formulation differentiation	Limited
Manufacturing know-how	Moderate
Sterile fill-finish capability	Moderate to high
Supply-chain advantage	Commercially meaningful
Biosimilar exposure	None
Generic price pressure	High

Manufacturing execution is the main barrier. The formulation is simple, but sterile injectable production is not. Failure points include particulate contamination, container breakage, extractables, fill-volume variability, endotoxin excursions, and facility inspection findings.

What litigation and settlement risks exist?

The conventional product presents low expected patent-litigation risk. If a later patent is listed, a Paragraph IV filing could trigger litigation under the Hatch-Waxman framework. The most plausible disputes would concern:

• A specific dosage strength or presentation.
• A later-developed container system.
• A manufacturing or sterilization process.
• A formulation parameter claimed as clinically relevant.
• A branded product with a separate delivery technology.

Settlement agreements would be commercially relevant only if they restrict launch timing, limit product presentation, or allocate supply rights. A standard generic entrant should not assume that a settlement involving another bupivacaine product applies to hyperbaric bupivacaine in dextrose.

How does it compare with liposomal bupivacaine?

Attribute	Bupivacaine HCl with dextrose	Liposomal bupivacaine
Product type	Conventional solution	Extended-release particulate formulation
Typical use	Spinal anesthesia	Local infiltration and selected regional techniques
Excipient role	Dextrose controls density	Lipid delivery system controls release
Patent position	Mature and weak	More complex and potentially stronger
Regulatory pathway	Generic 505(j) is plausible	Complex formulation and clinical assessment
Price profile	Low-cost institutional product	Premium branded or specialty product
Main barrier	Sterile manufacturing and supply	Formulation, clinical evidence, and patent estate

The two products should not be treated as interchangeable. Their routes, administration techniques, clinical uses, and regulatory strategies differ.

What generic entry risks exist?

Generic entry risk is high because the formulation is old, the active ingredient is well characterized, and the product can potentially be developed through an ANDA. A branded supplier’s defenses are primarily commercial:

• Maintain reliable inventory.
• Protect hospital contracts.
• Differentiate package configurations.
• Offer dependable distributor service.
• Reduce back-order exposure.
• Demonstrate quality consistency.
• Bundle the product with a broader anesthesia portfolio.

Price erosion may be rapid after additional entrants. The most defensible position is usually the lowest sustainable cost structure combined with supply reliability.

Key Takeaways

• Bupivacaine hydrochloride with dextrose is a mature hyperbaric spinal anesthetic.
• The standard formulation is 0.75% bupivacaine hydrochloride in 8.25% dextrose, preservative-free.
• Dextrose is a functional excipient because it controls solution density and spinal distribution.
• The conventional product has no apparent material current patent or exclusivity barrier.
• A 505(j) ANDA is the most direct regulatory route for a matching generic.
• Biosimilar risk is irrelevant because bupivacaine is a small molecule.
• Commercial value depends on sterile manufacturing, packaging, supply reliability, and hospital contracting.
• Novel packaging, prefilled systems, density-controlled formulations, and sustained-release technologies offer greater differentiation than the basic solution.
• Liposomal bupivacaine is a separate product category with different regulatory and patent economics.
• Generic entry and price erosion risk are high.

FAQs

Is dextrose an active ingredient in hyperbaric bupivacaine?

No. Dextrose is an excipient, but it has a critical functional role because it increases solution density and produces a hyperbaric spinal anesthetic.

Can plain bupivacaine injection replace bupivacaine with dextrose?

Not automatically. Plain bupivacaine lacks the same density characteristics and is not a direct formulation substitute for hyperbaric intrathecal bupivacaine.

Is bupivacaine hydrochloride with dextrose a biologic?

No. Bupivacaine hydrochloride is a chemically synthesized small-molecule drug. Generic competition proceeds through the ANDA pathway rather than the biosimilar pathway.

What is the main CMC risk for a generic hyperbaric bupivacaine product?

The main risks are sterile manufacturing, particulate control, container compatibility, density consistency, endotoxin control, and stability across the proposed shelf life.

Can a sponsor patent a new bupivacaine-dextrose formulation?

Potentially, but a patent would need a novel and non-obvious technical feature. A simple change in concentration or container configuration may face substantial prior-art and obviousness challenges.

References

1. DailyMed. (2024). Bupivacaine hydrochloride in dextrose injection prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database. FDA.

4. Pfizer Laboratories. (2023). Marcaine and Marcaine with epinephrine prescribing information. Pfizer Inc.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.